Otonomy begins mid-stage trial of OTO-313 in tinnitus

Apr. 11, 2019 8:52 AM ETOtonomy, Inc. (OTIC)By: Mamta Mayani, SA News Editor
  • Otonomy (NASDAQ:OTIC) has initiated a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus.
  • The study will include an initial safety cohort followed by an exploratory efficacy study that will enroll  approx.50 patients with subjective tinnitus.
  • Results from the trial are expected in H1 2020.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.